Normocalcemic Primary hyperparathyroidism: 99mTc SestaMibi SPECT/ | 61137
Endocrinology & Metabolic Syndrome

Endocrinology & Metabolic Syndrome
Open Access

ISSN: 2161-1017

+44 7868 792050

Normocalcemic Primary hyperparathyroidism: 99mTc SestaMibi SPECT/CT results compare with hypercalcmic hyperparathyroidism

Global Summit on Endocrinology

August 22-23, 2022 | Webinar

Martina Musumeci

Hospital Italiano de Buenos Aires, Argentina

Scientific Tracks Abstracts: Endocrinol Metab Syndr

Abstract :

Normocalcemic primary hyperparathyroidism (nPHPT) is defined by an inappropriately increased serum PTH with normal serum calcium. Information about the diagnostic yield of parathyroid SPECT/CT scan and ultrasonography in nHPPT is limited and not conclusive. Purpose: To evaluate the positivity rate of 99mTc? Sestamibi SPECT/CT scan in nPHTP compared with classical hypercalcemic PHPT (cPHPT). Materials and Methods: We retrospectively studied 125 patients with 99mTc?Sestamibi SPECT/CT scans. Subjects were divided into 2 groups: cPHPT (n = 93) and nPHPT (n = 32). Results: The detection rate of 99mTc?Sestamibi SPECT/CT in cPHPT was 86,02% (80/93) and 59.37%, in nPHPT (19/32), p = .003. No significant differences were seen between the SPECT/CT scan and ultrasonography (p = .28) and the agreement was higher in cPHPT than in nPHPT, p = .03. Sensitivity of 99m Tc?Sestamibi?SPECT/CT was 98% on a per?patient basis (PPV 96%) and 91% on a per?lesion basis (PPV 88%). Glandular size was smaller in nPHPT (mean value 6.8 mm) and it was related only with PTH value. Conclusion: Localization rate of parathyroid hyperfunctioning tissue with 99mTc?Sestamibi SPECT/CT is lower in nPHPT and it is related to a smaller glandular size. However, our study suggests that the positivity rate and sensitivity are non negligible by adding SPECT/CT. The reduction in the detection rate in nPHPT could benefit techniques with higher resolution such as 18F?Choline PET/CT when the clinical context justifies it.

Biography :

Martina Musumeci has completed her Medicine career at the age of 25 years from La Plata University and postdoctoral studies in Endocrinology and in Nuclear Medicine from Buenos Aires University. She is a doctor associate at Nuclear Medicine and PET/CT department in Hospital Italiano de Buenos Aires and Alexander Fleming Institute, in Buenos Aires, Argentina. She has published different papers in molecular images in hyperparathyroidism which is her field of expertise.

Top globaltechsummit